Table 4 Treatment-related adverse events in the propensity score-matched cohort

Hypertension

40 (35.4%)

39 (34.5%)

1 (0.9%)

0

46 (40.7%)

44 (38.9%)

2 (1.8%)

0

0.41

1.0

Fatigue

80 (70.8%)

80 (70.8%)

0

0

45 (39.8%)

44 (38.9%)

1 (0.9%)

0

<0.001

1.0

Fever

16 (14.2%)

16 (14.2%)

0

0

4 (3.5%)

4 (3.5%)

0

0

0.005

Sensory neuropathy

42 (37.2%)

42 (37.2%)

0

0

12 (10.6%)

11 (9.7%)

1 (0.9%)

0

<0.001

1.0

Edema

15 (13.3%)

15 (13.3%)

0

0

8 (7.1%)

7 (6.2%)

1 (0.9%)

0

0.12

1.0

Alopecia

23 (20.4%)

23 (20.4%)

0

0

4 (3.5%)

4 (3.5%)

0

0

<0.001

Abdominal pain

64 (56.6%)

63 (55.8%)

1 (0.9%)

0

60 (53.1%)

57 (50.4%)

2 (1.8%)

1 (0.9%)

0.59

0.62

Nausea

84 (74.3%)

82 (72.6%)

2 (1.8%)

0

62 (54.9%)

59 (52.2%)

3 (2.7%)

0

0.002

1.0

Vomit

46 (40.7%)

39 (34.5%)

7 (6.2%)

0

33 (29.2%)

29 (25.7%)

4 (3.5%)

0

0.07

0.35

diarrhea

29 (25.7%)

24 (21.2%)

5 (4.4%)

0

19 (16.8%)

19 (16.8%)

0

0

0.10

0.06

Neutropenia

21 (18.6%)

19 (16.8%)

1 (0.9%)

1 (0.9%)

12 (10.6%)

10 (8.9%)

2 (1.8%)

0

0.09

1.0

Anemia

79 (69.9%)

78 (69.0%)

1 (0.9%)

0

66 (58.4%)

66 (58.4%)

0

0

0.071

1.0

Thrombocytopenia

56 (49.6%)

54 (47.8%)

2 (1.8%)

0

45 (39.8%)

38 (33.6%)

4 (3.5%)

3 (2.7%)

0.14

0.17

Elevated ALT

81 (71.7%)

68 (60.2%)

13 (11.5%)

0

73 (64.6%)

68 (60.2%)

5 (4.4%)

0

0.25

0.049

Elevated AST

112 (99.2%)

73 (64.6%)

37 (32.7%)

2 (1.8%)

105 (92.9%)

82 (72.6%)

20 (17.7%)

3 (2.7%)

0.041

0.017

Hyperbilirubinemia

55 (48.7%)

54 (47.8%)

1 (0.9%)

0

50 (44.3%)

48 (42.5%)

2 (1.8%)

0

0.51

1.0

Elevated CRE

11 (9.7%)

11 (9.7%)

0

0

27 (23.9%)

27 (23.9%)

0

0

0.004

Hypoalbuminemia

104 (92.0%)

104 (92.0%)

0

0

104 (92.0%)

104 (92.0%)

0

0

1.000

Prolonged PT

55 (48.7%)

55 (48.7%)

0

0

29 (25.7%)

29 (25.7%)

0

0

<0.001

Grade 3–4 AE

0.043